Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma

Fei, Zhaodong; Xu, Ting; Li, Mengying; Chen, Taojun; Li, Li; Qiu, Xianxin; Chen, Chuanben

doi:10.1186/s13014-020-01674-5

Cited by 16 publications

(21 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fujian Province has carried out screening for nasopharyngeal cancer for long time. The precise treatment can reduce the cost of treatment and improve the survival rate of patients [22]. For females, the incidence rate of breast cancer is the highest in both areas.…”

Section: Discussionmentioning

confidence: 99%

Survival of cancer patients in Fujian, Southeast China: a population-based cancer registry study

Zhou¹,

Xiang²,

Ma³

et al. 2021

neo

View full text Add to dashboard Cite

Survival rates are usually used to evaluate the effect of cancer treatment and prevention. No study has focused on the characteristic of population-based cancer survival in Fujian, which is regarded as one of the high-risk areas of cancer in China. This study aims to analyze the 5-year relative survival of patients in Fujian Province using population-based cancer registry data. A total of 8 population-based registries in Fujian Province reported cancer cases diagnosed in 2012-2014.Relative survival was calculated as the ratio between observed survival and expected survival. The 5-year relative survival for all cancers combined was 36.19% and the age-standardized 5-year relative survival for all patients was 31.80%. Females had higher relative survival than males (38.90% and 27.00%). The patients in urban areas had a higher relative survival than those in rural areas (32.34% and 31.29%). Lung, gastric, liver, colorectal, and esophageal cancers were the five most common cancers, with 5-year relative survival below 50%. This is the first study that evaluated the population-based cancer relative survival in Fujian, China. Our study suggests that the overall survival of cancer patients in Fujian Province is poor. Furthermore, the results of this study can be used as a baseline for further research in Fujian, and provide important evidence for cancer etiology research.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival of cancer patients in Fujian, Southeast China: a population-based cancer registry study

Zhou¹,

Xiang²,

Ma³

et al. 2021

neo

View full text Add to dashboard Cite

show abstract

“…All chemotherapy regimens were administered according to a previously described protocol [ 13 ]. Patients with stage I disease received radiotherapy alone.…”

Section: Methodsmentioning

confidence: 99%

“…All patients received intensity-modulated radiotherapy (IMRT), and the target volume and dose of radiotherapy were calculated using a previously described treatment protocol [ 13 , 14 ]. In brief, the planning target volumes obtained for the primary gross tumor volume or gross tumor volume in the involved lymph nodes were exposed to a total dose of 70 Gy in 31–35 fractions.…”

Section: Methodsmentioning

confidence: 99%

Reflecting on the utility of standardized uptake values on 18F-FDG PET in nasopharyngeal carcinoma

Qiu

et al. 2022

BMC Cancer

Self Cite

View full text Add to dashboard Cite

Background To rethink the clinical significance of standardized uptake values (SUVs) of nasopharyngeal carcinoma (NPC) on 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography (PET). Methods We retrospectively reviewed 369 NPC patients who underwent pretreatment 18F-FDG PET. The predictive value of the SUVmax of the primary tumor (SUVmax-t) and regional lymph nodes (SUVmax-n) was evaluated using probability density functions. Receiver operating characteristic curves were used to determine optimal cutoffs for the SUVmax-n/SUVmax-t ratio (NTR). Kaplan–Meier and Cox regression analyses were used to assess survival. Results The optimal SUVmax-t and SUVmax-n cutoffs were 7.5 and 6.9, respectively. High SUVmax-t and SUVmax-n were related to local and regional recurrence, respectively. Patients with low SUVmax had better 3-year overall survival (OS). To avoid cross-sensitization of cutoff points, we stratified patients with high SUVmax into the low and high NTR groups. The 3-year distant metastasis-free survival (DMFS; 92.3 vs. 80.6%, P = 0.009), progression-free survival (PFS; 84.0 vs. 67.7%, P = 0.011), and OS (95.9 vs. 89.2%, P = 0.002) significantly differed between the high vs. low NTR groups for patients with high SUVmax. Multivariable analysis showed that NTR was an independent prognostic factor for DMFS (hazard ratio [HR]: 2.037, 95% CI: 1.039–3.992, P = 0.038), PFS (HR: 1.636, 95% CI: 1.021–2.621, P = 0.041), and OS (HR: 2.543, 95% CI: 1.214–5.325, P = 0.013). Conclusion High SUVmax was associated with NPC recurrence. NTR is a potential prognosticator for DMFS, suggesting that heterogeneity in the pretreatment 18F-FDG uptake between the primary tumor and lymph nodes is associated with high invasion and metastatic potential.

show abstract

“…Zhao et al (29) found that nimotuzumab plus CCRT for locally advanced nasopharyngeal carcinoma can signi cantly improve the 3-year OS, compared with CCRT alone (98.0% vs. 91.0%, P = 0.032). Marta et al…”

Section: Adverse Eventsmentioning

confidence: 99%

Efficacy and safety of Nimotuzumab combined with chemoradiotherapy in the treatment of locally advanced cervical cancer

Zhang

Jiang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Platinum-based concurrent chemoradiotherapy (CCRT) is the primary treatment for locally advanced cervical cancer (LACC). Improving the efficacy of LACC treatment is the focus of clinical research. This study aimed to investigate the efficacy and safety of nimotuzumab combined with CCRT compared with CCRT for treating LACC.Methods: Patients with LACC treated at the Affiliated Hospital of Qingdao University from March 2017 to December 2019 were collected and classified into Nimotuzumab plus chemoradiotherapy (N+CCRT) group and concurrent chemoradiotherapy (CCRT) group. Histological subtype was collected. The primary endpoints were overall survival (OS) and progression-free survival (PFS), as well as the secondary endpoints were Complete response rate (CRR), objective response rate (ORR), and adverse events (AEs).Results: A total of 120 patients (65 in the N+CCRT group and 55 in the CCRT group) were enrolled with a median follow-up time of 37 months. In N+CCRT group, 1-, 2-, and 3-year OS rates were 98.46%, 95.38% and 90.50%, 1-, 2-, and 3-year cumulative PFS rates were 89.23%, 83.08% and 79.73%, CRR was 86.15% (56/65), the ORR was 92.31% (60/65), respectively. In CCRT group, 1-, 2-, and 3-year OS rates were 94.55%, 87.27%, and 78.18%, 1-, 2-, and 3-year PFS rates were 81.82%, 69.09% and 59.69%, CRR was 70.91% (39/55), ORR was 87.27% (48/55), respectively. CRR (86.15% vs. 70.91%, P=0.040) and 3-year PFS rates (79.73% vs. 59.69%, P=0.039) were significantly higher in N+CCRT group. AEs during treatment mainly included bone marrow suppression, gastrointestinal reactions, radiation enteritis, hepatic impairment, and radiation cystitis, and there was no significant difference between the two groups (P > 0.05).Conclusion: Nimotuzumab combined with CCRT enhanced PFS and CRR for LACC patients and was well tolerated.

show abstract

Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma

Cited by 16 publications

References 29 publications

Survival of cancer patients in Fujian, Southeast China: a population-based cancer registry study

Survival of cancer patients in Fujian, Southeast China: a population-based cancer registry study

Reflecting on the utility of standardized uptake values on 18F-FDG PET in nasopharyngeal carcinoma

Efficacy and safety of Nimotuzumab combined with chemoradiotherapy in the treatment of locally advanced cervical cancer

Contact Info

Product

Resources

About